tetano
Editor, Senior Moderator
Biomark Med
. 2022 Feb 18.
doi: 10.2217/bmm-2021-0536. Online ahead of print.
Biomarker evaluation for prognostic stratification of patients with COVID-19: the added value of quantitative chest CT
Roberto M Ferreira[SUP] 1 2 [/SUP], Gabriel Ss de Oliveira[SUP] 1 2 [/SUP], João Rf da Rocha[SUP] 1 2 [/SUP], Felipe de Mc Ribeiro[SUP] 3 [/SUP], João J Stern[SUP] 3 [/SUP], Rangel de S Costa[SUP] 3 [/SUP], Ricardo N Lemgruber[SUP] 1 [/SUP], Júlia Fp Ramalho[SUP] 1 [/SUP], Alexandre Cp de Almeida[SUP] 1 [/SUP], Pedro Pn Sampaio[SUP] 1 2 [/SUP], João Mansur Filho[SUP] 1 [/SUP], Ricardo Ac Lima[SUP] 1 4 [/SUP]
Affiliations
Abstract
Aim: Pulmonary disease burden and biomarkers are possible predictors of outcomes in patients with COVID-19 and provide complementary information. In this study, the prognostic value of adding quantitative chest computed tomography (CT) to a multiple biomarker approach was evaluated among 148 hospitalized patients with confirmed COVID-19. Materials & methods: Patients admitted between March and July 2020 who were submitted to chest CT and biomarker measurement (troponin I, D-dimer and C-reactive protein) were retrospectively analyzed. Biomarker and tomographic data were compared and associated with death and intensive care unit admission. Results: The number of elevated biomarkers was significantly associated with greater opacification percentages, lower lung volumes and higher death and intensive care unit admission rates. Total lung volume <3.0 l provided further stratification for mortality when combined with biomarker evaluation. Conclusion: Adding automated CT data to a multiple biomarker approach may provide a simple strategy for enhancing risk stratification of patients with COVID-19.
Keywords: CRP; D-dimer; biomarkers; coronavirus; prognosis; tomography; troponin.
. 2022 Feb 18.
doi: 10.2217/bmm-2021-0536. Online ahead of print.
Biomarker evaluation for prognostic stratification of patients with COVID-19: the added value of quantitative chest CT
Roberto M Ferreira[SUP] 1 2 [/SUP], Gabriel Ss de Oliveira[SUP] 1 2 [/SUP], João Rf da Rocha[SUP] 1 2 [/SUP], Felipe de Mc Ribeiro[SUP] 3 [/SUP], João J Stern[SUP] 3 [/SUP], Rangel de S Costa[SUP] 3 [/SUP], Ricardo N Lemgruber[SUP] 1 [/SUP], Júlia Fp Ramalho[SUP] 1 [/SUP], Alexandre Cp de Almeida[SUP] 1 [/SUP], Pedro Pn Sampaio[SUP] 1 2 [/SUP], João Mansur Filho[SUP] 1 [/SUP], Ricardo Ac Lima[SUP] 1 4 [/SUP]
Affiliations
- PMID: 35176874
- DOI: 10.2217/bmm-2021-0536
Abstract
Aim: Pulmonary disease burden and biomarkers are possible predictors of outcomes in patients with COVID-19 and provide complementary information. In this study, the prognostic value of adding quantitative chest computed tomography (CT) to a multiple biomarker approach was evaluated among 148 hospitalized patients with confirmed COVID-19. Materials & methods: Patients admitted between March and July 2020 who were submitted to chest CT and biomarker measurement (troponin I, D-dimer and C-reactive protein) were retrospectively analyzed. Biomarker and tomographic data were compared and associated with death and intensive care unit admission. Results: The number of elevated biomarkers was significantly associated with greater opacification percentages, lower lung volumes and higher death and intensive care unit admission rates. Total lung volume <3.0 l provided further stratification for mortality when combined with biomarker evaluation. Conclusion: Adding automated CT data to a multiple biomarker approach may provide a simple strategy for enhancing risk stratification of patients with COVID-19.
Keywords: CRP; D-dimer; biomarkers; coronavirus; prognosis; tomography; troponin.